Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets (2016 - 2025)

Historic Assets for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $823.6 million.

  • Corcept Therapeutics' Assets rose 501.75% to $823.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $823.6 million, marking a year-over-year increase of 501.75%. This contributed to the annual value of $840.6 million for FY2024, which is 3524.22% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Assets is $823.6 million, which was up 501.75% from $801.7 million recorded in Q2 2025.
  • Corcept Therapeutics' Assets' 5-year high stood at $846.5 million during Q1 2025, with a 5-year trough of $423.8 million in Q4 2021.
  • In the last 5 years, Corcept Therapeutics' Assets had a median value of $594.0 million in 2023 and averaged $633.5 million.
  • In the last 5 years, Corcept Therapeutics' Assets crashed by 2588.19% in 2021 and then skyrocketed by 3768.06% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Assets stood at $423.8 million in 2021, then surged by 37.68% to $583.4 million in 2022, then grew by 6.53% to $621.5 million in 2023, then soared by 35.24% to $840.6 million in 2024, then fell by 2.02% to $823.6 million in 2025.
  • Its Assets stands at $823.6 million for Q3 2025, versus $801.7 million for Q2 2025 and $846.5 million for Q1 2025.